Because cancer vaccine immunotherapy in GBM is a different paradigm. MOA such as delayed impact, PFS, absence of side effects, tumor stabilization, possible crossover confoundment, pseudo progression, etc. These are all more complex than a topline result could define without context. Add to that the new definition of GBM.
Just giving TLD would not capture all the observations and insights necessary to understand the study results and its endpoints regardless if they’re excellent or something more mixed.
(I should note that I think manufacturing readiness preparation is another element regarding the present delay. A very critical part.)
Market Data 
Markets 
AI
